VolitionRX (NYSEAMERICAN:VNRX) Given Hold Rating at D. Boral Capital

D. Boral Capital reiterated their hold rating on shares of VolitionRX (NYSEAMERICAN:VNRX) in a research report report published on Monday,Benzinga reports.

A number of other research analysts also recently weighed in on the company. HC Wainwright dropped their price target on VolitionRX from $1.50 to $1.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd. Citigroup downgraded VolitionRX to a “hold” rating in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat, VolitionRX has an average rating of “Moderate Buy” and a consensus target price of $2.33.

VolitionRX Price Performance

Shares of VolitionRX stock opened at $0.16 on Monday. VolitionRX has a one year low of $0.15 and a one year high of $0.94. The stock’s 50-day moving average is $0.20 and its 200 day moving average is $0.29. The firm has a market cap of $25.86 million, a price-to-earnings ratio of -0.74 and a beta of 1.33.

Shares of VolitionRX are set to reverse split on the morning of Tuesday, April 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Tuesday, March 31st. The medical research company reported ($0.05) EPS for the quarter, meeting the consensus estimate of ($0.05). The business had revenue of $0.45 million for the quarter, compared to the consensus estimate of $0.71 million. On average, sell-side analysts expect that VolitionRX will post -0.11 EPS for the current fiscal year.

Institutional Trading of VolitionRX

Several institutional investors and hedge funds have recently modified their holdings of the stock. Lagoda Investment Management L.P. raised its stake in shares of VolitionRX by 6.7% in the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock worth $8,476,000 after purchasing an additional 782,000 shares during the last quarter. Armistice Capital LLC raised its stake in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock worth $6,367,000 after purchasing an additional 887,351 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of VolitionRX by 9.8% in the fourth quarter. Geode Capital Management LLC now owns 963,986 shares of the medical research company’s stock worth $246,000 after purchasing an additional 85,816 shares during the last quarter. Citadel Advisors LLC raised its stake in shares of VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock worth $224,000 after purchasing an additional 135,775 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new stake in shares of VolitionRX in the fourth quarter worth approximately $34,000. 8.09% of the stock is owned by hedge funds and other institutional investors.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.